Curbing Antibiotic Prophylaxis Doesn't Up Endocarditis Risk

This article originally appeared here.
Share this content:
Curbing Antibiotic Prophylaxis Doesn't Up Endocarditis Risk
Curbing Antibiotic Prophylaxis Doesn't Up Endocarditis Risk

(HealthDay News) – The incidence of viridans group streptococci infective endocarditis (VGS-IE) has not increased since the publication of the 2007 American Heart Association (AHA) guidelines restricting prophylactic antibiotics in dental patients.

To investigate the incidence of VGS-IE since publication of the 2007 AHA guidelines, Daniel C. DeSimone, MD, from the Mayo Clinic in Rochester, MN, and colleagues reviewed all definite or possible cases of VGS-IE (1999–2010) using data from the Rochester Epidemiology Project of Olmsted County, MN. In addition, they examined the Nationwide Inpatient Sample hospital discharge database for VGS-IE cases (1999–2009).

During the 12-year study period, the researchers identified 22 cases of VGS-IE in Olmsted County. Incidence rates (per 100,000 person-years) were 3.19 for 1999–2002, 2.48 for 2003–2006, and 0.77 for 2007–2010 (P=0.061 from Poisson regression). The national number of hospital discharges with a VGS-IE diagnosis ranged from 15,318–15,938 in 1999–2002; from 16,214–17,433 for 2003–2006; and from 14,728–15,479 in 2007–2009.

"Despite marked changes in IE prevention guidelines that were published by the AHA in 2007 that restricted antibiotic prophylaxis to four patient groups with a high risk of complications from IE, the findings of our population-based investigation from Olmsted County suggest that the incidence of VGS-IE after publication of these guidelines did not increase," the authors conclude.

One author disclosed financial ties to UpToDate Inc.; a second author disclosed ties to TyRx Inc.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs